筛选
全部清除
发表时间
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
产品类型
Luc阴性对照慢病毒
研究领域
肿瘤
神经
代谢
内脏
mRNA疫苗
膀胱癌
细胞癌
肝脏
前列腺癌
细胞转录
乳腺癌
视网膜细胞癌
直肠癌
炎症
阿兹海默症
卵巢癌
甲状腺癌
宫颈癌
急性髓系白血病
高血糖
糖尿病
冠状病毒
胃癌
其他
结直肠癌
头颈癌
肾炎
肝癌
肺癌
肺腺癌
鼻咽癌
胰腺癌
骨癌
减肥
哮喘
免疫
肾癌
当前位置:资源中心 > 客户文献
客户文献
共 233 内容
IF=12.658,Journal of Experimental & Clinical Cancer Research,中山大学附属第一医院,ARE-luc, HRE-luc , NF-κB-luc , FOXO-luc SMAD- luc,TCF-1-luc报告基因质粒
ALG3 contributes to stemness and radioresistance through regulating glycosylation of TGF-β receptor II in breast cancer
IF=13.933,Metabolism Clinical and Experimental,中国科学院大学,miRNA过表达AAV
MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice
IF=12.067,Cell Death & Differentiation,南京医科大学基础医学院病理学系,永生化慢病毒
Epithelium-and endothelium-derived exosomes regulate the alveolar macrophages by targeting RGS1 mediated calcium signaling-dependent immune response
IF=15.254,BRAIN,浙江大学医学院,干扰慢病毒
Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy
IF=16.744,Chemical Engineering Journal,天津大学医学工程与转化医学研究院,S蛋白假病毒
Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
IF=17.521,Advanced Science,上海市新药设计重点实验室,过表达慢病毒
Multi‐Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation
IF=10.334,Pharmacological Research,中国科学院上海药物研究所,过表达AAV
New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice
IF=11.6,Theranostics,中国药科大学中药学院,过表达质粒,sgRNA质粒
The role of GLS1-mediated glutaminolysis/2-HG/H3K4me3 and GSH/ROS signals in Th17 responses counteracted by PPARγ agonists
IF=38.102,Signal Transduction and Targeted Therapy,广西国际纳米抗体研究中心,过表达质粒
Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
IF=31.791,Gut,复旦大学,siRNA合成
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism
首页 15 16 17 18 19 末页
共 24 页
跳转
当前位置:资源中心 > 客户文献

客户文献
共 233 内容
IF=12.658,Journal of Experimental & Clinical Cancer Research,中山大学附属第一医院,ARE-luc, HRE-luc , NF-κB-luc , FOXO-luc SMAD- luc,TCF-1-luc报告基因质粒
ALG3 contributes to stemness and radioresistance through regulating glycosylation of TGF-β receptor II in breast cancer
IF=13.933,Metabolism Clinical and Experimental,中国科学院大学,miRNA过表达AAV
MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice
IF=12.067,Cell Death & Differentiation,南京医科大学基础医学院病理学系,永生化慢病毒
Epithelium-and endothelium-derived exosomes regulate the alveolar macrophages by targeting RGS1 mediated calcium signaling-dependent immune response
IF=15.254,BRAIN,浙江大学医学院,干扰慢病毒
Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy
IF=16.744,Chemical Engineering Journal,天津大学医学工程与转化医学研究院,S蛋白假病毒
Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
IF=17.521,Advanced Science,上海市新药设计重点实验室,过表达慢病毒
Multi‐Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation
IF=10.334,Pharmacological Research,中国科学院上海药物研究所,过表达AAV
New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice
IF=11.6,Theranostics,中国药科大学中药学院,过表达质粒,sgRNA质粒
The role of GLS1-mediated glutaminolysis/2-HG/H3K4me3 and GSH/ROS signals in Th17 responses counteracted by PPARγ agonists
IF=38.102,Signal Transduction and Targeted Therapy,广西国际纳米抗体研究中心,过表达质粒
Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
IF=31.791,Gut,复旦大学,siRNA合成
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism
MORE
筛选
全部清除
发表时间
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
产品类型
Luc阴性对照慢病毒
研究领域
肿瘤
神经
代谢
内脏
mRNA疫苗
膀胱癌
细胞癌
肝脏
前列腺癌
细胞转录
乳腺癌
视网膜细胞癌
直肠癌
炎症
阿兹海默症
卵巢癌
甲状腺癌
宫颈癌
急性髓系白血病
高血糖
糖尿病
冠状病毒
胃癌
其他
结直肠癌
头颈癌
肾炎
肝癌
肺癌
肺腺癌
鼻咽癌
胰腺癌
骨癌
减肥
哮喘
免疫
肾癌
重置
确定
Tel: 400-627-9288
留言咨询
重置
提交
客服
微信
电话
留言
留言咨询
重置
提交